Theriva Biologics ( (TOVX) ) has provided an update.
Theriva Biologics, Inc. has received a €2.28 million boost from the Spanish government to enhance its THERICEL project in collaboration with the Universitat Autònoma de Barcelona, aiming to revolutionize the clinical manufacture of viral therapies. The funds, structured as a €1.33 million loan and a €0.95 million grant to UAB, will propel the development of a suspension cell platform, potentially lowering manufacturing costs and improving efficiency. This investment not only underscores the innovative potential of Theriva’s therapeutic approach but also sets the stage for faster advancement in oncolytic virus development and gene therapy.
For detailed information about TOVX stock, go to TipRanks’ Stock Analysis page.